Some extracts from the 4C
- Imminent release of interim DARRT-1 clinical data
- Major opportunity identified for Veyonda in growing radiopharmaceutical use
- To the best of the Company’s knowledge, Veyonda is the only drug being developed with the critical dual actions of enhancing the cancer-killing effect of radiation (by increasing cancer cell chromosomal damage and blocking the cell’s ability to repair the damage); and stimulating the body’s innate immune system.
Ann: Appendix 4C - Quarterly, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14000 | 1 |
View Market Depth
| Last trade - 10.11am 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
